

ACCELERATING TREATMENT FOR AGE-RELATED DISEASES THROUGH COLLABORATION OF DAMAGE/REPAIR MODEL EXPERTISE

RB2015 Speakers:

Chas Bountra, SGC Oxford Chief Scientist,
Professor of Translational Medicine, Nuffield
Department of Clinical Medicine and Associate
Member of the Department of Pharmacology,
University of Oxford

Judy Campisi, *Professor*, Buck Institute for Research on Aging

Mitch Finer, Chief Science Officer, Bluebird Bio

Jeffrey Karp, Associate Professor, Brigham and Women's Hospital, Harvard Medical School

Jeanne Loring, Professor, Scripps Research Institute

Nancy Manley, Professor, Cellular Biology, Franklin College

Jan Vijg, Ph.D. Professor, Department of Genetics; Professor, Department of Ophthalmology & Visual Sciences and Chair, Department of Genetics, Albert Einstein School of Medicine.

Back by popular demand! Hal Sparks - Actor, Comedian & Musician, entertains the RB2015 audience

What's new for 2015:

- 1. Focused tracks covering three key elements of successful drug development: clinical review, therapeutic approaches and industry and policy
- 2. In depth examination of advances in tissue engineering and gene therapy
- 3. More interactivity! 6 hours of interactive discussion sessions and 17 hours of networking
- Jobs board review and share the expertise needs of the industry's leading research and development organizations
- Understand and shape the scientific and investment opportunities of the new Rejuvenation Biotechnology industry
- 6. Extended poster sessions

August 19-21, 2015 Hyatt Regency San Francisco Airport

t SENS Research Foundation we have a vision of creating a rejuvenation biotechnology industry, the aim of which is to accelerate drug development through an unprecedentedly broadbased collaboration of damage-repair expertise.

Why? Well, it's clear to us all that the prevalence of age-related diseases is spiraling and the socioeconomic impacts are a constant source of concern. Consequently, interest in preventing such diseases through novel approaches to drug development is at an all-time high – but it can be a slow and laborious process. We believe that collaboration from therapeutic area specialists, particularly in the damage repair fields, is crucial to changing the shape of the industry and, ultimately, improving and saving lives.

The Rejuvenation Biotechnology
Conference is the latest SENS
Research Foundation meeting and
will be held on August 19-21, 2015
at the Hyatt Regency San Francisco
Airport in Burlingame, California.
We would love to welcome you
to this ground-breaking gathering
of the growing rejuvenation
biotechnology industry, to discuss

combinatorial, preventative strategies and to progress treatment for the diseases and disabilities of old age. In order to make real change, we need to engage with all the stakeholders of the rejuvenation biotech world, which is why our meeting is unique in the sense that it brings together experts from research, academia, industry, policy, finance and regulatory fields.

Please peruse the meeting agenda and register your place – Super Early Bird Pricing is in place until June 15th.

We look forward to seeing you in Burlingame.

With best wishes,

Mile Arbrer



Mike Kope CEO



Aubrey de Grey Chief Science Officer

Keep in touch... join the conversation!

About the

sens research foundation

reimagine aging

At SENS Research Foundation, we believe that a world free of age-related disease is possible. That's why we're funding work at universities across the world and at our own Research Center in Mountain View, CA.

Our research emphasizes the application of regenerative medicine to age-related disease, with the intent of repairing underlying damage to the body's tissues, cells, and molecules. Our goal is to help build the industry that will cure the diseases of aging.

SENS Research Foundation is a research-focused outreach organization. Our outreach efforts include the annual Rejuvenation Biotechnology Conferences, the SENS conferences at Cambridge, speaking engagements, and general advocacy. We strive to inform policymakers and the public about the promise of the damage repair approach to treating agerelated diseases.

Conference Day 1: Wednesday August 19, 2015

7:30 am Registration (until 5:00 pm)

7:30 am Breakfast

9:00 am Opening Remarks

9:30 am Keynote Address

10:30 am CONCURRENT SESSIONS:

Track 1: Age-Related Diseases

Cancer: Novel Biomarkers and Therapeutic Targets

- Judith Campisi, Professor, Buck Institute for Research on Aging
- Jan Viig, Professor, Department of Genetics; Professor, Department of Ophthalmology & Visual Sciences; Chair, Department of Genetics, Albert Einstein School of Medicine.

Track 2: Therapeutic Approaches Advances in Tissue Engineering

- Anthony Atala, Director, Wake Forest Institute for Regenerative Medicine;
 W.H. Boyce Professor and Chair, Department of Urology at Wake Forest University
- Nancy Manley, *Professor*, Cellular Biology, Franklin College
- Stewart Abbott, Senior Director Stem Cells, Celgene Cellular Therapeutics

Track 3: Translation to Treatment Economics in Healthcare

12:00 am Lunch Break and Exhibits Open

1:30 am CONCURRENT SESSIONS:

Alzheimer's and Neurodegenerative Disease part 1

- John Trojanowski, Professor of Geriatric Medicine and Gerontology, Perelman School of Medicine, University of Pennsylvania
- Tony Wyss-Coray, Professor of Neurology, Stanford School of Medicine
- Doug Ethell, Professor & Head Molecular Neurobiology, GCBS Western University of Health Sciences

Applications in Gene Therapy

 Philip Gregory, Chief Scientific Officer, Sangamo BioSciences Inc.

Investment and Industry

3:00 pm Break in Exhibit Area

3:30 pm Economic and Demographic Influences on Healthcare in an Aging Population

The evolution of our healthcare system will be impacted enormously by our aging population. This evolution may be impacted by radical changes in how age-related disease is defined, how treatments for those diseases are delivered, and how consumers receive healthcare. Is the current healthcare system prepared to respond to all of these factors? Or would alternative healthcare models be better prepared to cope?

4:30 pm How to Invest in a Rejuvenation Biotechnology Industry

This panel will discuss the new and significant types of investment opportunities offered by the intersection of regenerative medicine and the development of treatments for age-related disease. As new technologies for age-related disease emerge from the bench, new challenges in product development, regulatory licensing, and preventative intervention also emerge. Will new investment structures that recognize and address these issues be key to driving drug and therapeutic development?


5:30 pm Reception in Exhibits Area / Poster Session

7:00 pm Dinner

8:00 pm Dessert in Exhibits Area / Poster Session

9:00 pm Performance by Comedian Hal Sparks

Currently starring in the Disney XD show, LAB RATS, actor/comedian Hal Sparks began his professional career as a teenager in Chicago. As a member of the famed Second City Troupe, his quick wit and affable personality quickly gained him recognition and acclaim and he was named the "Funniest Teenager In Chicago" by the Chicago Sun Times. Sparks went on to host the Emmy Award- winning "Talk Soup" on E! Entertainment Television, winning rave reviews from fans and critics alike. He starred for five seasons on Showtime's hit series "Queer As Folk" and appeared in the films "Extract," "Spiderman 2" and "Dude, Where's My Car?" Sparks recently starred in his own one hour Showtime comedy special, "Charmageddon," which is now a best-selling DVD. He is a star commentator on VH1's popular "I Love the 80's" series and can be hear every Wednesday on the nationally syndicated "Stephanie Miller Radio Show." Hal is also a pop culture expert and regularly appears on such shows as "Joy Behar" and CNN's "Your Money." His numerous other television appearances include "The Tonight Show," "Larry King Live," "Charlie Rose," "Good Morning America," "The View," "Jimmy Kimmel" and MTV. In addition to a busy acting and stand-up career, he is an accomplished musician. Hal and his band, Zero 1, recently released their debut album.



Conference Day 2: Thursday August 20, 2015

7:30 am Registration (until 5:00 pm)

7:30 am Breakfast

9:00 am Opening Remarks

9:30 am Keynote Address

10:30 am CONCURRENT SESSIONS:

Track 1: Age-Related Diseases

Cancer: Immunotherapy

- Mitch Finer, Chief Science Officer, Bluebird Bio
- Marc Better, Vice President Product Sciences, Kite Pharma

Track 2: Therapeutic Approaches Advances in Stem Cell Research

- Jeanne Loring, *Professor*, Scripps Research Institute
- Evan Snyder, Director, Center for Stem Cell and Regenerative Medicine, Director, Stem Cell Research Center and Core Facility Sanford-Burnham Medical Research Institute

Track 3: Translation to Treatment Investment and Industry Part 2

12:00 am Lunch Break and Exhibits Open

1:30 am CONCURRENT SESSIONS:

Alzheimer's and Neurodegenerative Disease part 2

 Chas Bountra, SGC Oxford Chief Scientist, Professor of Translational Medicine, Nuffield Department of Clinical Medicine; Associate Member, Department of Pharmacology, University of Oxford

Advances in Stem Cell Applications

• Jeff Karp, Associate Professor, Brigham and Women's Hospital, Harvard Medical School

Regulatory Issues in Regenerative Medicine part 2

- Russ Altman, Chair, Department of Bioengineering; Director, Program in Biomedical Informatics, , Stanford Medical School
- Stephen Spielberg, Editor-in-Chief, Therapeutic Innovation & Regulatory Science

3:00 pm Break in Exhibit Area

3:30 pm Changing Perspectives of Aging

The world's leading regenerative medicine and gerontological research organizations significantly drive the discussion on the connections between the biology of aging and chronic disease. How are the definitions of aging and age-related disease themselves changing? What are the changes in institutional and research drivers in this evolving dialogue?

4:30 pm Emerging Alzheimer's Strategies

Perhaps nowhere has research into the biology of aging and research into the treatment of disease intersected so strongly as with Alzheimer's research and drug development. The connections between government, advocacy, research and industrial players have become robust and sophisticated especially as evidenced by cooperative alliances such as ACT-AD. Basic research into underlying causes has developed into translational research for preventative and disease-modifying interventions, even as clinical research stretches towards earlier intervention and challenges the traditional notions of how the disease is defined and when it strikes. Is this an emerging example of the rejuvenation biotechnology paradigm in action? If so, what are the implications for the future of Alzheimer's drug and therapeutic development? Could any of the lessons learned from Alzheimer's be applied to other neurodegenerative diseases?

- 5:30 pm Reception in Exhibits Area / Poster Session
- 7:00 pm Dinner
- 8:00 pm Dessert in Exhibits Area / Poster Session

Conference Day 3: Friday August 21, 2015

- 7:30 am Registration (until 5:00 pm)
- 7:30 am Breakfast
- 9:00 am Opening Remarks
- 9:30 am Keynote Address
- 10:30 am CONCURRENT SESSIONS:

Track 1: Age-Related Diseases

Advances in Cardiovascular Disease Research and Treatment

 Jay Jerome, Associate Professor and Director, Graduate Program in Cellular and Molecular Pathology, Vanderbilt University Medical Center

Track 2: Therapeutic Approaches

Beyond Disease Silos: Intervention Strategies Against Aging

- Brian Kennedy, CEO and Professor, Buck Institute For Research on Aging
- Jerry Shay, *Professor*, UT Southwestern Medical Center
- Rita Effros, Professor, Pathology and Laboratory Medicine, David Geffen School of Medicine, UCLA

Track 3: Translation to Treatment

Regulatory Issues in Regenerative Medicine Part 2

12:00 pm Lunch Break and Exhibits Open

1:30 pm How will regulatory science keep pace with changes in healthcare for age-related disease?

There is increasing emphasis on the development of licensing processes that can accommodate a world in which both healthcare technologies and healthcare delivery is changing rapidly. What are some of the strategies being implemented, research programs being developed, and challenges remaining for this field to keep pace with innovations in regenerative medicine?

2:30 pm Building a Rejuvenation Biotechnology Industry

This panel will synthesize the discussions from all of the preceding sessions and panels. A cross-section of academic, industrial and policy leaders from throughout the conference will revisit the merits of a Rejuvenation Biotechnology Paradigm to address the diseases of aging. Panelists will consider recent developments in the emergence of this industry, its opportunities, and its challenges.

3:30 pm Closing Remarks

Sponsorship Opportunities

What is Rejuvenation Biotechnology?

The prevalence of age-related diseases is spiralling and the socioeconomic impacts are a constant source of debate. As such, interest in treating preventing such diseases is at an all-time high.

RB2015 is the only event where you find all of the crucial stakeholders that drive progression in rejuvenation biotechnology; scientific, business and venture capital experts across Alzheimer's, cancer and cardiovascular disease.




2014 Audience Breakdown:

Academic Researchers

Industry

Nonprofit

Students



For more information on the event, sponsorship packages and availability, visit the website or email nicola.ambler@sens.org and we'll send you the latest updates.

"I found the conference extremely well organized, the speakers exciting, and the overall feeling to be warm and encouraging. I enjoyed meeting a diverse group of attendees."

- RB2014 delegate



Pricing	SUPER EARLY BIRD (expires June 15th)	EARLY BIRD (expires July 15th)	Standard Rate (until August 19th)
Students, Post Docs & Non Profits	\$400	\$500	\$600
Academics & professors	\$595	\$795	\$995
Industry	\$1395	\$1595	\$1795
Vendors/Service Providers	\$1695	\$1995	\$2195



Conference Registration Includes:

- Full access to all Sessions
- Full access to Receptions
- Special Wednesday Night Hal Sparks Performance
- Continental Breakfast, Lunch and Dinner
- PM Refreshment Breaks
- Exhibitor Reception

Click here to register for the conference

Travel and Hotel Information

The Rejuvenation Biotechnology Conference will be held at the Hyatt Regency San Francisco Airport Hotel. A limited number of rooms have been reserved for the Rejuvenation Biotechnology Conference at the discounted rate of \$209 per night. Book your reservation today.





There's no need to trade comfort for convenience when you can have both at our Burlingame hotel. Hyatt Regency San Francisco Airport is a sophisticated hotel located 15 minutes from downtown San Francisco and just a short drive from San Francisco Airport (SFO). Guests have named it as one of the top rated hotels in the entire region, winning TripAdvisor's Certificate of Excellence Award in 2014.

Hyatt Regency San Francisco Airport

1333 Old Bayshore Hwy
Burlingame, CA 94010

Tel: +1 650.347.1234

Map and Directions

To receive the Rejuvenation Biotechnology Conference special rate <u>click here for your reservation</u>.



Rejuvenation Biotechnology Conference



"The biggest additional benefit for me was the networking and interaction with others working in the same field as me, which was far better than anticipated."

"The networking opportunities were excellent; as well as the scientific presentations."





"Thank you Dr. de Grey and all at SENS Research Foundation for a substance-packed (and entertaining!) three days."